A detailed history of Morgan Jess S & CO Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Morgan Jess S & CO Inc holds 49,090 shares of NVCR stock, worth $1.19 Million. This represents 3.25% of its overall portfolio holdings.

Number of Shares
49,090
Previous 48,345 1.54%
Holding current value
$1.19 Million
Previous $3.36 Million 11.01%
% of portfolio
3.25%
Previous 3.48%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 21, 2022

BUY
$67.99 - $89.57 $50,652 - $66,729
745 Added 1.54%
49,090 $3.73 Million
Q2 2022

Jul 18, 2022

SELL
$56.6 - $89.9 $29,149 - $46,298
-515 Reduced 1.05%
48,345 $3.36 Million
Q1 2022

May 16, 2022

BUY
$60.15 - $84.52 $293,832 - $412,880
4,885 Added 11.11%
48,860 $4.05 Million
Q4 2021

Jan 27, 2022

BUY
$75.08 - $121.99 $802,980 - $1.3 Million
10,695 Added 32.14%
43,975 $3.3 Million
Q3 2021

Nov 09, 2021

BUY
$116.17 - $194.55 $1.1 Million - $1.85 Million
9,505 Added 39.98%
33,280 $3.87 Million
Q2 2021

Nov 30, 2021

SELL
$130.4 - $225.58 $287,792 - $497,855
-2,207 Reduced 8.49%
23,775 $5.27 Million
Q1 2021

Nov 30, 2021

SELL
$124.11 - $190.17 $279,247 - $427,882
-2,250 Reduced 7.97%
25,982 $3.43 Million
Q4 2020

Nov 30, 2021

SELL
$112.16 - $174.14 $538,368 - $835,871
-4,800 Reduced 14.53%
28,232 $4.89 Million
Q3 2020

Nov 29, 2021

SELL
$58.05 - $111.31 $168,925 - $323,912
-2,910 Reduced 8.1%
33,032 $3.68 Million
Q2 2020

Nov 29, 2021

SELL
$57.2 - $74.41 $333,876 - $434,331
-5,837 Reduced 13.97%
35,942 $2.13 Million
Q1 2020

Nov 29, 2021

SELL
$57.05 - $95.75 $633,825 - $1.06 Million
-11,110 Reduced 21.01%
41,779 $2.81 Million
Q4 2019

Nov 19, 2021

BUY
$68.3 - $93.8 $3.61 Million - $4.96 Million
52,889 New
52,889 $4.46 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.54B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Morgan Jess S & CO Inc Portfolio

Follow Morgan Jess S & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Jess S & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Jess S & CO Inc with notifications on news.